Innovating Works

H2020

Cerrada
HORIZON-HLTH-2021-DISEASE...
HORIZON-HLTH-2021-DISEASE-04-01: Improved supportive, palliative, survivorship and end-of-life care of cancer patients
ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 21-09-2021.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio..
Esta ayuda financia Proyectos:

ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

Reduced health-related suffering and improved well-being and quality of life for cancer patients in need of supportive, palliative, survivorship or end-of-life care as well as for their professional and family caregivers.Cancer patients (independently of their age) have early and better access to supportive, palliative, survivorship or end-of-life care services of higher quality and (cost)effectiveness.Reduced societal, healthcare and economic burden associated with increasing demands of supportive, palliative, survivorship or end-of-life care services that is beneficial for citizens and preserves the sustainability of the health care systems.Health care providers and health policy makers have access to and use improved clinical guidelines and policies with respect to pain management, psychological and/or spiritu... ver más

ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

Reduced health-related suffering and improved well-being and quality of life for cancer patients in need of supportive, palliative, survivorship or end-of-life care as well as for their professional and family caregivers.Cancer patients (independently of their age) have early and better access to supportive, palliative, survivorship or end-of-life care services of higher quality and (cost)effectiveness.Reduced societal, healthcare and economic burden associated with increasing demands of supportive, palliative, survivorship or end-of-life care services that is beneficial for citizens and preserves the sustainability of the health care systems.Health care providers and health policy makers have access to and use improved clinical guidelines and policies with respect to pain management, psychological and/or spiritual support, and supportive, palliative, survivorship or end-of-life care for cancer patients.Cancer patients and their professional and family caregivers use the improved evidence-based and information-driven palliative care decision-making process.
Scope:The complexity of health conditions related to cancer and late or long-term side effects as consequences of its treatments affect the quality of life of cancer patients and their families and pose a significant societal and economic burden. Palliative[1], supportive[2], survivorship and end-of-life care approaches improve the quality of life for cancer patients and professional and family caregivers through the prevention and relief of suffering by means of early identification, assessment and treatment of pain and other problems such as physical, psychosocial and spiritual problems. Although a variety of interventions are in use, they are often insufficiently validated or adapted to the specific needs of cancer patients and cancer survivors, often affected by co- or multi-morbidities. Thus, there is a need to strengthen the evidence base for patient-centred, effective interventions improving the quality of life and outcomes of cancer patients and cancer survivors of all ages in the domains of supportive, palliative, survivorship and end-of-life care.

Proposals should address all of the following activities:

Demonstrate the effectiveness and cost-effectiveness of newly proposed or specifically adapted pharmacological and/or non-pharmacological interventions to improve well-being and the quality of life of cancer patients. Serious late and long-term side effects of cancer treatments or symptoms that occur at the end of life of those patients as well as of cancer survivors should be considered. The legal and ethical aspects of the proposed interventions should be taken into consideration and be fully addressed.Prove the feasibility of integrating the proposed interventions in current pain management, palliative, supportive, survivorship and/or end-of-life care regimes and healthcare systems across Europe. The complex human, social, cultural and ethical aspects that are necessarily managed by those care regimes and healthcare systems should be reflected from the patients’ perspectives as well as those of their professional and family caregivers. The views and values of patients and their caregivers (including families, volunteers, nurses and others) should also be appropriately taken into account in patient-centred care decisions.Identify and analyse relationships between sex, gender, age, disabilities and socio-economic factors in health and any other relevant factors (e.g. ethical, familial, cultural considerations, including personal beliefs and religious perspectives, etc.) that could affect health equity[3] of the proposed interventions, including equitable access.

Analyse the barriers and opportunities to re-invigorating and enhancing timely social inclusion and active engagement of cancer patients in need of supportive, palliative, survivorship and end-of-life care and their caregivers.Provide guidelines for patient-centred communication as well as standards for evidence-based communication trainings for caregivers, considering the potential of social innovation approaches or tools.When relevant, provide policy recommendations for pain management, psychological and/or spiritual support, and supportive, palliative, survivorship or end-of-life care of cancer patients afflicted by late and long-term side effects of cancer treatments. Randomised clinical trials and observational studies, targeting children or adults or elderly, should be considered for this topic. Proposals should give a sound feasibility assessment, provide details of the methodology, including an appropriate patient selection and realistic recruitment plans, justified by available publications and/or preliminary results.

This topic requires effective contributions from the social sciences and humanities (SSH) through the involvement of SSH experts and institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities. Proposals should consider a patient-centred approach that empowers patients, promotes a culture of dialogue and openness between health professionals, patients and their families, and unleashes the potential for social innovation.

All projects funded under this topic are strongly encouraged to participate in networking and joint activities, as appropriate. These networking and joint activities could, for example, involve the participation in joint workshops, the exchange of knowledge, the development and adoption of best practices, or joint communication activities. This could also involve networking and joint activities with projects funded under other clusters and pillars of Horizon Europe, or other EU programmes, as appropriate. Therefore, proposals are expected to include a budget for the attendance to regular joint meetings and may consider to cover the costs of any other potential joint activities without the prerequisite to detail concrete joint activities at this stage. The details of these joint activities will be defined during the grant agreement preparation phase. In this regard, the Commission may take on the role of facilitator for networking and exchanges, including with relevant stakeholders, if appropriate.


Cross-cutting Priorities:Social InnovationSocietal EngagementSocio-economic science and humanities


[1]https://www.who.int/cancer/palliative/definition/en/

[2]https://www.mascc.org/about-mascc

[3]https://www.who.int/topics/health_equity/en/



ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Subcontracting costs.
Purchase costs.
Other cost categories.
Indirect costs.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 4:. Es el primer paso para determinar si los componentes individuales funcionarán juntos como un sistema en un entorno de laboratorio. Es un sistema de baja fidelidad para demostrar la funcionalidad básica y se definen las predicciones de rendimiento asociadas en relación con el entorno operativo final. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
Para el presupuesto subvencionable la intensidad de la ayuda en formato fondo perdido podrá alcanzar como minimo un 100%.
The funding rate for RIA projects is 100 % of the eligible costs for all types of organizations. The funding rate for RIA projects is 100 % of the eligible costs for all types of organizations.
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda no tiene efecto incentivador. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
HORIZON-HLTH-2021-DISEASE-04 Improved supportive, palliative, survivorship and end-of-life care of cancer patients ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Sin info.
HORIZON-HLTH-2021-DISEASE-04-07 Personalised medicine and infectious diseases: understanding the individual host response to viruses (e.g. SARS-CoV-2)
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 3 años | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2021-DISEASE-04-01 Improved supportive, palliative, survivorship and end-of-life care of cancer patients
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 3 años | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2021-DISEASE-04-03 Innovative approaches to enhance poverty-related diseases research in sub-Saharan Africa
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 3 años | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2021-DISEASE-04-02 Building a European innovation platform for the repurposing of medicinal products
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 3 años | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2021-DISEASE-04-06 Building a European partnership for pandemic preparedness
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 3 años | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2021-DISEASE-04-05 A roadmap towards the creation of the European partnership on One Health antimicrobial resistance (OH AMR)
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 3 años | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2021-DISEASE-04-04 Clinical validation of artificial intelligence (AI) solutions for treatment and care
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 3 años | Próxima convocatoria prevista para el mes de